Iron isomaltoside 1000

Overview

Iron isomaltoside 1000 is under investigation in Iron Deficiency Anaemia. Iron isomaltoside 1000 has been investigated for the treatment and basic science of Anemia, Gastric Cancer, Esophageal Cancer, Chronic Kidney Disease, and Anemia, Iron-Deficiency, among others.

Indication

No indication information available.

Associated Conditions

Iron Deficiency (ID)
Iron Deficiency Anemia (IDA)

Clinical Trials

Title	Posted	Study ID	Phase	Status	Sponsor
Comparing High and Low Dose Iron Treatments for People on Peritoneal Dialysis: The PALaDIN Study	2025/03/19	NCT06884280	Phase 3	Not yet recruiting	Hull University Teaching Hospitals NHS Trust
Iron Isomaltide for Iron-deficiency Anemia Patients With Locally Advanced Nasopharyngeal Carcinoma	2023/06/22	NCT05913414	Phase 2	Recruiting	Sun Yat-sen University
The Effect of Intravenous Iron Therapy and Erythropoiesis-stimulation Agent Combination on Renal Transplant Outcomes	2023/02/09	NCT05719376	Phase 4	Not yet recruiting	Yonsei University
Oral Versus Intravenous Iron in IBD Patients With Anti-inflammatory Therapy.	2022/10/14	NCT05581420	Not Applicable	Recruiting	Leiden University Medical Center
Single Dose Intravenous Iron Isomaltoside in Combination With Oral Iron vs Oral Iron Monotherapy in Patients With Anemia After Postpartum Haemorrhage	2020/08/10	NCT04505514	Phase 4	UNKNOWN	University of Malaya
Real Life Study on Iron Isomaltoside 1000 in the Treatment of ID in CKD, Heart Failure, ObGyn, IBD, Cancer and Elective Surgery (Real-CHOICE).	2020/03/24	NCT04318405	N/A	Completed	Pierre Fabre Pharma AG
Effect of Intravenous Iron Supplementation in Reducing Allogenic Blood Transfusion	2019/08/20	NCT04061655	Early Phase 1	Completed	Ain Shams University
ProPBM : A Modified Patient Blood Management Protocol	2019/03/25	NCT03888768	Not Applicable	UNKNOWN	Ministry of Health, Malaysia
Intravenous Iron Supplement for Iron Deficiency in Cardiac Transplant Recipients	2018/09/07	NCT03662789	Phase 2	Completed	Oslo University Hospital
Effect of IV Iron Isomaltoside on Postoperative Anemia in Total Knee Arthroplasty Patients	2018/03/20	NCT03470649	Not Applicable	Completed	Seoul National University Hospital

FDA Drug Approvals

Approved Product	Manufacturer	NDC Code	Route	Strength	Effective Date
No FDA approvals found for this drug.

EMA Drug Approvals

Approved Product	Authorization Holder	Status	Issued Date
No EMA approvals found for this drug.

HSA Drug Approvals

Approved Product	Manufacturer	Approval Number	Dosage Form	Strength	Approval Date
No HSA approvals found for this drug.

NMPA Drug Approvals

Approved Product	Company	Approval Number	Drug Type	Dosage Form	Approval Date
No NMPA approvals found for this drug.

PPB Drug Approvals

Approved Product	Registration No.	Company	Licence No.	Strength	Registration Date
No PPB approvals found for this drug.

TGA Drug Approvals

Approved Product	ARTG ID	Sponsor	Registration Type	Status	Registration Date
No TGA approvals found for this drug.

AI-Powered Research

Premium Access